JP2022523360A5 - - Google Patents

Info

Publication number
JP2022523360A5
JP2022523360A5 JP2021549279A JP2021549279A JP2022523360A5 JP 2022523360 A5 JP2022523360 A5 JP 2022523360A5 JP 2021549279 A JP2021549279 A JP 2021549279A JP 2021549279 A JP2021549279 A JP 2021549279A JP 2022523360 A5 JP2022523360 A5 JP 2022523360A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021549279A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523360A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/019126 external-priority patent/WO2020172475A1/en
Publication of JP2022523360A publication Critical patent/JP2022523360A/ja
Publication of JP2022523360A5 publication Critical patent/JP2022523360A5/ja
Pending legal-status Critical Current

Links

JP2021549279A 2019-02-21 2020-02-20 Metに結合する抗met抗体および二特異性抗原結合分子を使用した眼癌の治療方法 Pending JP2022523360A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962808839P 2019-02-21 2019-02-21
US62/808,839 2019-02-21
US201962823788P 2019-03-26 2019-03-26
US62/823,788 2019-03-26
PCT/US2020/019126 WO2020172475A1 (en) 2019-02-21 2020-02-20 Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met

Publications (2)

Publication Number Publication Date
JP2022523360A JP2022523360A (ja) 2022-04-22
JP2022523360A5 true JP2022523360A5 (enExample) 2022-12-14

Family

ID=70057228

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021549279A Pending JP2022523360A (ja) 2019-02-21 2020-02-20 Metに結合する抗met抗体および二特異性抗原結合分子を使用した眼癌の治療方法

Country Status (11)

Country Link
US (1) US20220040319A1 (enExample)
EP (1) EP3927435A1 (enExample)
JP (1) JP2022523360A (enExample)
KR (1) KR20210130755A (enExample)
CN (1) CN113727757A (enExample)
AU (1) AU2020224136C1 (enExample)
CA (1) CA3128519A1 (enExample)
IL (1) IL285308A (enExample)
MX (1) MX2021010114A (enExample)
SG (1) SG11202108525VA (enExample)
WO (1) WO2020172475A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
WO2022204332A1 (en) * 2021-03-24 2022-09-29 Combangio, Inc. Compositions comprising c-met agonist antibodies and methods for use in ocular treatment
CN117098804B (zh) 2021-10-01 2026-02-06 株式会社Lg化学 热塑性树脂组合物
CA3256857A1 (en) * 2022-06-29 2024-01-04 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. EGFR/MET ANTIBODIES AND THEIR USES

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5646036A (en) 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
ATE465257T1 (de) 1996-07-03 2010-05-15 Genentech Inc Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
CN1922208A (zh) 2003-12-11 2007-02-28 健泰科生物技术公司 用于抑制c-met二聚化及活化的方法和组合物
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
ME01803B (me) 2004-08-05 2010-12-31 Genentech Inc Humanizovani anti-cmet antagonisti
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
US7985557B2 (en) 2007-05-23 2011-07-26 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
UA108598C2 (xx) 2008-04-30 2015-05-25 Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
ES2560807T3 (es) 2008-07-21 2016-02-22 Polytherics Limited Nuevos reactivos y procedimiento de conjugación de moléculas biológicas
KR101000067B1 (ko) 2008-12-30 2010-12-10 엘지전자 주식회사 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
DK2889624T3 (en) 2009-08-10 2018-12-10 Ucl Business Plc Reversible covalent bonding of functional molecules
PT2528625E (pt) 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
DK2714685T3 (en) 2011-05-27 2017-01-09 Ambrx Inc FORMATIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID BOUND dolastatin
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EP2758430A4 (en) 2011-09-20 2015-06-03 Lilly Co Eli ANTI-C-MET ANTIBODY
AU2012322934B2 (en) 2011-10-14 2016-09-08 Medimmune Limited Pyrrolobenzodiazepines
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
JP6166728B2 (ja) 2011-10-14 2017-07-19 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体
CA2850375C (en) 2011-10-14 2019-07-02 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
BR112014013526A8 (pt) 2011-12-05 2017-06-13 Igenica Biotherapeutics Inc conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
CA2869316C (en) 2012-05-09 2016-12-20 Eli Lilly And Company Anti-c-met antibodies
HRP20180268T4 (hr) 2012-10-23 2026-03-27 Synaffix B.V. Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu
EP3964237B1 (en) 2013-03-15 2026-02-18 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
AU2014311361B2 (en) 2013-08-26 2018-11-29 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
TW201609805A (zh) 2013-12-23 2016-03-16 美國禮來大藥廠 結合egfr及met之多功能抗體
CA2978340C (en) 2015-03-27 2024-05-28 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
MX390630B (es) 2016-01-25 2025-03-21 Regeneron Pharma Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
TWI782930B (zh) * 2016-11-16 2022-11-11 美商再生元醫藥公司 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法
DK3544634T3 (da) * 2016-11-23 2021-06-07 Lilly Co Eli MET-antistof-lægemiddelkonjugater

Similar Documents

Publication Publication Date Title
JP7118117B2 (ja) 抗体-薬物コンジュゲートの選択的製造方法
JP7564991B2 (ja) Sema4d抗体及びその製造方法と使用
CN102421802B (zh) 人源化的axl抗体
JP2025111463A (ja) Dll3結合タンパク質および使用方法
JP2021527431A5 (enExample)
JP2019532056A5 (enExample)
RU2754684C2 (ru) Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171)
JP2023539501A (ja) 抗vegf-抗pd-l1二重特異性抗体、その医薬組成物およびその使用
JP2018531219A (ja) Pd−l1抗体
EP3307274A1 (en) Cd123 antibodies and conjugates thereof
US20120251554A1 (en) Anti-cd33 antibodies and use thereof for immunotargeting in treating cd33-associated illnesses
JP2024523003A (ja) Dll3標的化三重特異性タンパク質およびそれらの使用方法
AU2015249887A1 (en) Novel anti-RNF43 antibodies and methods of use
JP2025183307A5 (enExample)
JP2021501571A (ja) 抗cd3抗体およびそれを含む癌処置用医薬組成物
JP2021523100A5 (enExample)
TWI908815B (zh) 用於人類疾病之治療的cd38抗體
JP2021521245A (ja) キレート化された放射性核種に対する抗体および除去剤
AU2017254674A1 (en) Novel anti-BMPR1B antibodies and methods of use
JP2021531263A (ja) 抗ヒトpd−l1抗体とその使用
JP2023546293A5 (enExample)
JP2024540536A5 (enExample)
JP2025509338A (ja) Ror1標的結合分子とその使用
US20030180799A1 (en) Antibodies against plasma cells
US20250197501A1 (en) Recombinant antibody, immunoconjugate comprising the same, and uses thereof in treating cancers